Laura Barisoni

Laura Barisoni

Auto-generated profile, based on publicly available information

Laura Barisoni

Division of AI and Computational Pathology, Department of Pathology, Duke University, Durham, North Carolina

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2020 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
LBLaura Barisoni
Laura Barisoni
KLKyle J. Lafata
Kyle J. Lafata
SHStephen M. Hewitt
Stephen M. Hewitt
AMAnant Madabhushi
Anant Madabhushi
UBUlysses G. J. Balis
Ulysses G. J. Balis

10 June 2022 in Science Advances
Verified
Journal Article
Open access
JHJens Hansen
Jens Hansen
RSRachel Sealfon
Rachel Sealfon
RMRajasree Menon
Rajasree Menon
MEMichael Eadon
Michael Eadon
BLBlue B. Lake
Blue B. Lake
KPKidney Precision Medicine Project
Kidney Precision Medicine Project
Kidney Precision Medicine Project (KPMP) is building a spatially specified human kidney tissue atlas in health and disease with single-cell resolution. Here, we describe the construction of an integrated reference map of cells, pathways, and genes using unaffected regions of nephrectomy tissues and undiseased human biopsies from 56 adult subjects. We use single-cell/nucleus transcriptomics, subsegmental laser microdissection transcriptomics and proteomics, near-single-cell proteomics, 3D and CODEX imaging, and spatial metabolomics to hierarchically identify genes, pathways, and cells. Integrated data from these different technologies coherently identify cell types/subtypes within different nephron segments and the interstitium. These profiles describe cell-level functional organization of the kidney following its physiological functions and link cell subtypes to genes, proteins, metabolites, and pathways. They further show that messenger RNA levels along the nephron are congruent with the subsegmental physiological activity. This reference atlas provides a framework for the classification of kidney disease when multiple molecular mechanisms underlie convergent clinical phenotypes.

16 September 2020 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
EOEdison Ong
Edison Ong
LWLucy L. Wang
Lucy L. Wang
JSJennifer Schaub
Jennifer Schaub
JOJohn F. O’tOole
John F. O’tOole
BSBecky Steck
Becky Steck
KPKidney Precision Medicine Project
Kidney Precision Medicine Project

15 October 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
ADAnil Dangi
Anil Dangi
NNNaveen R. Natesh
Naveen R. Natesh
IHIrma Husain
Irma Husain
ZJZhicheng ji
Zhicheng ji
LBLaura Barisoni
Laura Barisoni
XLXunrong Luo
Xunrong Luo
Myeloid cells are increasingly recognized as major players in transplant rejection. Here, we used a murine kidney transplantation model and single cell transcriptomics to dissect the contribution of myeloid cell subsets and their potential signaling pathways to kidney transplant rejection. Using a variety of bioinformatic techniques, including machine learning, we demonstrate that kidney allograft–infiltrating myeloid cells followed a trajectory of differentiation from monocytes to proinflammatory macrophages, and they exhibited distinct interactions with kidney allograft parenchymal cells. While this process correlated with a unique pattern of myeloid cell transcripts, a top gene identified was Axl , a member of the receptor tyrosine kinase family Tyro3/Axl/Mertk (TAM). Using kidney transplant recipients with Axl gene deficiency, we further demonstrate that Axl augmented intragraft differentiation of proinflammatory macrophages, likely via its effect on the transcription factor Cebpb. This, in turn, promoted intragraft recruitment, differentiation, and proliferation of donor-specific T cells, and it enhanced early allograft inflammation evidenced by histology. We conclude that myeloid cell Axl expression identified by single cell transcriptomics of kidney allografts in our study plays a major role in promoting intragraft myeloid cell and T cell differentiation, and it presents a potentially novel therapeutic target for controlling kidney allograft rejection and improving kidney allograft survival.

2 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MWMatthew B. Wright
Matthew B. Wright
JSJavier Varona Santos
Javier Varona Santos
CKChristian Kemmer
Christian Kemmer
CMCyrille Maugeais
Cyrille Maugeais
JCJean-Philippe Carralot
Jean-Philippe Carralot
AFAlessia Fornoni
Alessia Fornoni
Impaired cellular cholesterol efflux is a key factor in the progression of renal, cardiovascular, and autoimmune diseases. Here we describe a class of 5-arylnicotinamide compounds, identified through phenotypic drug discovery, that upregulate ABCA1-dependent cholesterol efflux by targeting Oxysterol Binding Protein Like 7 (OSBPL7). OSBPL7 was identified as the molecular target of these compounds through a chemical biology approach, employing a photoactivatable 5-arylnicotinamide derivative in a cellular cross-linking/immunoprecipitation assay. Further evaluation of two compounds (Cpd A and Cpd G) showed that they induced ABCA1 and cholesterol efflux from podocytes in vitro and normalized proteinuria and prevented renal function decline in mouse models of proteinuric kidney disease: Adriamycin-induced nephropathy and Alport Syndrome. In conclusion, we show that small molecule drugs targeting OSBPL7 reveal an alternative mechanism to upregulate ABCA1, and may represent a promising new therapeutic strategy for the treatment of renal diseases and other disorders of cellular cholesterol homeostasis.

1 July 2022 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
JZJarcy Zee
Jarcy Zee
QLQian Liu
Qian Liu
ASAbigail R. Smith
Abigail R. Smith
JHJeffrey B. Hodgin
Jeffrey B. Hodgin
ARAvi Rosenberg
Avi Rosenberg
LMLaura H. Mariani
Laura H. Mariani
Background: Heterogeneity in disease course and treatment response among patients with MCD/FSGS necessitates a granular evaluation of kidney tissue features. This study aimed to identify histologic and ultrastructural descriptors of structural changes most predictive of clinical outcomes in the Nephrotic Syndrome Study Network (NEPTUNE). Methods: Forty-eight histologic (37 glomerular, 9 tubulointerstitial, 2 vascular) and 20 ultrastructural descriptors were quantified by applying the NEPTUNE Digital Pathology Scoring System to NEPTUNE kidney biopsies. Outcomes included time from biopsy to disease progression, first complete remission of proteinuria, and treatment response. Relative importance of pathology and clinical predictors was obtained from random forest models, and predictive discrimination was assessed. Results: Among 224 participants (34% Black, 24% Hispanic), model performance was excellent, with predictive discrimination of 0.9 for disease progression, 0.85 for complete remission, and 0.81 for treatment response. The most predictive descriptors of outcomes included both conventional—e.g., global sclerosis or segmental sclerosis and interstitial fibrosis/tubular atrophy—and novel features, including adhesion, interstitial foam cells, deflation, periglomerular fibrosis, mononuclear white blood cells, endothelial cell abnormalities, microvillous transformation, and acute tubular injury. Conclusions: The most predictive descriptors of clinical outcomes among MCD/FSGS patients reflected structural changes in multiple renal compartments. Reporting these descriptors should be standardized to guide prognostication of proteinuric glomerular diseases.